Clinical Trial Update: A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) [Phase 1]

View source ↗

Summary

The Phase 1 SAD/MAD study of ABC008 in Inclusion Body Myositis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inclusion Body Myositis

Drugs mentioned

• ABC008

Snippet

Sponsor: Abcuro, Inc. | Conditions: Inclusion Body Myositis | Phase 1 | Status: COMPLETED